Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Inflammatory Disorders Associated with Allergy: Overview of Immunopathogenesis and Implications for Treatment.

Corren J.

Immunol Allergy Clin North Am. 2017 May;37(2):233-246. doi: 10.1016/j.iac.2017.01.001. Epub 2017 Mar 3. Review.

PMID:
28366474
2.

Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.

Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA Jr, Peters SP, Farrar JR.

Ann Allergy Asthma Immunol. 2017 Feb;118(2):133-142.e3. doi: 10.1016/j.anai.2016.12.010.

PMID:
28153079
3.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.

Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.

PMID:
27130691
4.

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.

Corren J, Weinstein S, Janka L, Zangrilli J, Garin M.

Chest. 2016 Oct;150(4):799-810. doi: 10.1016/j.chest.2016.03.018. Epub 2016 Mar 25.

5.

Remodeling in Allergic Rhinitis. Adding New Data to an Old Debate.

Corren J, Togias A.

Am J Respir Crit Care Med. 2015 Dec 15;192(12):1403-4. doi: 10.1164/rccm.201510-1937ED. No abstract available.

6.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.

Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.

7.

Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform(®)) for the treatment of asthma.

Tan RA, Corren J.

Drug Des Devel Ther. 2014 Sep 30;8:1555-61. doi: 10.2147/DDDT.S36556. eCollection 2014. Review.

8.

Exacerbation-prone asthma--intrinsic to severe disease or a unique phenotype?

Corren J.

Clin Exp Allergy. 2014 Feb;44(2):152-3. doi: 10.1111/cea.12256. No abstract available.

PMID:
24447078
9.

Role of interleukin-13 in asthma.

Corren J.

Curr Allergy Asthma Rep. 2013 Oct;13(5):415-20. doi: 10.1007/s11882-013-0373-9. Review.

PMID:
24026573
10.
11.

Anti-interleukin-13 antibody therapy for asthma: one step closer.

Corren J.

Eur Respir J. 2013 Feb;41(2):255-6. doi: 10.1183/09031936.00124212. No abstract available.

12.

Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.

Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K.

Respir Med. 2013 Feb;107(2):180-95. doi: 10.1016/j.rmed.2012.10.025. Epub 2012 Dec 25.

13.

Inhibition of interleukin-5 for the treatment of eosinophilic diseases.

Corren J.

Discov Med. 2012 Apr;13(71):305-12. Review.

14.

Omalizumab in the treatment of asthma.

Tan R, Corren J.

Expert Rev Respir Med. 2011 Dec;5(6):747-56. doi: 10.1586/ers.11.73. Review.

PMID:
22082161
15.

Anti-interleukin-5 antibody therapy in asthma and allergies.

Corren J.

Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):565-70. doi: 10.1097/ACI.0b013e32834c3d30. Review.

PMID:
21971335
16.

Lebrikizumab treatment in adults with asthma.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG.

N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.

17.

The relationship of rhinitis and asthma, sinusitis, food allergy, and eczema.

Tan RA, Corren J.

Immunol Allergy Clin North Am. 2011 Aug;31(3):481-91. doi: 10.1016/j.iac.2011.05.010.

PMID:
21737039
18.

Safety of omalizumab in asthma.

Tan RA, Corren J.

Expert Opin Drug Saf. 2011 May;10(3):463-71. doi: 10.1517/14740338.2011.563840. Epub 2011 Mar 15. Review.

PMID:
21401438
19.

Cytokine inhibition in severe asthma: current knowledge and future directions.

Corren J.

Curr Opin Pulm Med. 2011 Jan;17(1):29-33. doi: 10.1097/MCP.0b013e3283413105. Review.

PMID:
21330823
20.

Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge.

Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, Fish JE.

J Allergy Clin Immunol. 2011 Feb;127(2):398-405. doi: 10.1016/j.jaci.2010.09.043.

PMID:
21281870

Supplemental Content

Loading ...
Support Center